Evidence map›Paper›PMID 40788517›Full record

ReviewDiscover oncology2025

The role of advanced diagnostics on precision medicine in hemato oncology.

Befikad Mandefro, Dereje Mengesha Berta, Amanuel Kelem, Bisrat Birke Teketelew, Abateneh Melkamu, Yalew Much, Zewdu Mulatie, Tiruneh Adane

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Befikad MandefroDepartment of Medical Laboratory Sciences, College of Medicine and Health Sciences, Debre Berhan University, Debre Berhan, Ethiopia. befikadm@gmail.com.
Dereje Mengesha BertaDepartment of Hematology and Immunohematology, School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.
Amanuel KelemDepartment of Medical Laboratory Sciences, College of Medicine and Health Sciences, Debre Berhan University, Debre Berhan, Ethiopia.
Bisrat Birke TeketelewDepartment of Hematology and Immunohematology, School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.
Abateneh MelkamuDepartment of Medical Laboratory Science, College of Medicine and Health Sciences, Debre Markos University, Debre Markos, Ethiopia.
Yalew MuchDepartment of Medical Laboratory Science, College of Medicine and Health Sciences, Debre Markos University, Debre Markos, Ethiopia.
Zewdu MulatieDepartment of Medical Laboratory Science, College of Medicine and Health Sciences, Wollo University, Wollo, Ethiopia.
Tiruneh AdaneDepartment of Hematology and Immunohematology, School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Advanced diagnostic technologies are driving precision medicine to revolutionize the field of hemato-oncology, that enable personalized treatments based on detailed molecular and genetic profiles. Innovations like next-generation sequencing, digital PCR, and liquid biopsies have reshaped diagnosis, classification, and treatment decisions in hematologic cancers such as leukemia, lymphoma, and myeloma. Each technology offers unique strengths NGS provides broad mutational insights, digital PCR enables ultra-sensitive measurable residual disease detection, and flow cytometry delivers rapid, accessible analysis while also facing specific limitations. This review explores how these tools collectively improve early detection, prognostication, and tailored therapy, enhancing patient outcomes. However, challenges persist, including tumor clonal diversity, microenvironmental influences, and unequal access due to cost and regulatory barriers. Future progress hinges on integrating multi-omics data, enhancing diagnostic accuracy, and expanding accessibility to fully harness personalized hemato-oncology, paving the way for more effective, individualized treatments and improved survival.

Indexed as

Advanced diagnosticsHemato-oncologyPrecision medicine

Identifiers

PMID40788517
PMCPMC12339839

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.